Skip to content
Homepage
Author:
STORM Therapeutics
Posted Date:
May 22, 2026
STORM Therapeutics to Present Promising Phase 1 Sarcoma Data Demonstrating Activity of First‑in‑Class METTL3 Inhibitor STC‑15 at ASCO 2026
STORM Therapeutics
May 22, 2026
STORM Therapeutics Secures $56 Million Series C Financing and Doses First Patient in Phase 2 Sarcoma Trial of STC‑15
STORM Therapeutics
April 16, 2026
